Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...
<shortened url>
i guess ccsvi is a"threat"
Multiple Sclerosis Market Forecast
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1744 Views
-
Last post by frodo
-
- 0 Replies
- 1773 Views
-
Last post by frodo
-
- 1 Replies
- 1929 Views
-
Last post by frodo
-
- 0 Replies
- 1912 Views
-
Last post by frodo
-
- 0 Replies
- 1402 Views
-
Last post by frodo
-
- 0 Replies
- 2063 Views
-
Last post by NHE
-
- 0 Replies
- 2449 Views
-
Last post by frodo
-
- 0 Replies
- 3805 Views
-
Last post by frodo
-
- 3 Replies
- 501 Views
-
Last post by Leonard